Sean Yan
No Rating Available
(Learn About Our Rating System)

Sean Yan, FACNM, MD

Languages spoken: English

Clinical Locations

Primary Location

University of Utah Hospital

Radiology
50 N Medical Dr
Salt Lake City , UT 84132
801-581-2121
Get Directions

  • Specialties

    Board Certification

    American Board of Nuclear Medicine (Nuclear Medicine) (ABNM)
    Specialists Accreditation Board (Nuclear Medicine) (SAB)

  • Board Certification and Academic Information

    Academic Departments Radiology & Imaging Sciences -Associate Professor (Clinical)
    Board Certification
    American Board of Nuclear Medicine (Nuclear Medicine) (ABNM)
    Specialists Accreditation Board (Nuclear Medicine) (SAB)

    Education history

    Professional Medical Clinical Medicine - Chongqing Medical University M.D.
    Graduate Training Radiological Medicine - Chongqing Medical University MMed
    Postdoctoral Training Charleston Area Medical Center Visiting Scholar
    Fellowship Vanderbilt University Medical Center Research Fellow
    Internship Family Medicine - University of Mississippi Medical Center Intern
    Internship Psychiatric Medicine - University of Alabama at Birmingham School of Medicine Intern
    Residency Internal Medicine - Icahn School of Medicine at Mount Sinai Resident
    Residency Nuclear Medicine - University of Tennessee Medical Center Resident
    Residency Nuclear Medicine - Vanderbilt University Medical Center Resident
    Fellowship Hybrid Imaging - Emory University School of Medicine, Emory University Hospital Fellow

    Selected Publications

    Journal Article

    1. Chen K, Tong AKT, Moe FNN, Ng DCE, Lo RHG, Gogna A, Yan SX, Thang SP, Loke KSH, Venkatanarasimha NK, Huang HL, Too CW, Ong TSK, Yeo EX, Peh DYY, Ng AWY, Yang L, Chan WY, Chang JPE, Goh BKP, Toh HC, Chow PK (2024). The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation. Liver cancer, 14(2), 158-179. (Read full publication)
    2. Tang CYL, Chua WM, Huang HL, Lam WW, Loh LM, Tai D, Ong SYK, Yan SX, Loke KSH, Ng DC, Tham W (2023). Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature. Journal of neuroendocrinology, 35(12), e13349. (Read full publication)
    3. Ngam PI, Tan E, Lim G, Yan S (2023). Improving (90)Y PET Scan Image Quality Through Optimized Reconstruction Algorithms. Journal of nuclear medicine technology, 51(1), 26-31. (Read full publication)
    4. He LM, Deng Y, Wang AB, Liu N, Chen Y, Yan XX, Zhang (2022). [Clinical Practice of (177)Lu-DOTATATE in the Treatment of Neuroendocrine Tumors]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 44(6), 1102-1106. (Read full publication)
    5. Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PK (2021). Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver cancer, 10(3), 224-239. (Read full publication)
    6. Tang T, Martin P, Somasundaram N, Lim C, Tao M, Poon E, Yunon MJ, Toh SQ, Yan SX, Farid M, Chan JY, Lim S (2021). Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma. Haematologica, 106(12), 3170-3175. (Read full publication)
    7. Nuclear Medicine Committee, Chinese Society of Clinical Oncology;, Beijing Nuclear Medicine Quality Control and Improvement Cente (2021). [Chinese expert consensus on selective internal radiation therapy with yttrium-90 for primary and metastatic hepatocellular carcinoma]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 29(7), 648-658. (Read full publication)
    8. Tham WY, Tong AKT, Loke KSH, Chio L, Lim GKY, Seah XY, Ng DCE, Yan SXX, Lam WW (2020). Divide and Conquer: Strategies in Singapore to Manage a Nuclear Medicine Department During COVID-19. Journal of nuclear medicine technology, 48(2), 98-101. (Read full publication)
    9. Chandran M, Chin YA, Choo KS, Ang WC, Huang XF, Liu XM, Tay D, Aung TKK, Ali A, Thu WPP, Logan S, Yan SX, Lekamwasam S, Hao (2020). Comparison of the Osteoporosis Self-Assessment Tool for Asians and the fracture risk assessment tool - FRAX to identify densitometric defined osteoporosis: A discriminatory value analysis in a multi-ethnic female population in Southeast Asia. Osteoporosis and sarcopenia, 6(2), 53-58. (Read full publication)
    10. Lu Y, Zhu X, Yan SX, Lan (2020). Emerging Attack and Management Strategies for Nuclear Medicine in Responding to COVID-19-ACNM Member Experience and Advice. Clinical nuclear medicine, 45(7), 534-535. (Read full publication)
    11. Suriyanto S, Ng EYK, Ng CED, Yan XS, Verma N (2019). (99m)Tc-MAG(3) diuresis renography in differentiating renal obstruction: Using statistical parameters as new quantifiable indices. Computers in biology and medicine, 112, 103371. (Read full publication)
    12. Chandran M, McCloskey EV, Thu WPP, Logan S, Hao Y, Tay D, Ang WC, Aung TKK, Choo KS, Ali A, Yan SX, Huang XF, Liu XM, Yong EL, Lekamwasam (2018). FRAX® based intervention thresholds for management of osteoporosis in Singaporean women. Archives of osteoporosis, 13(1), 130. (Read full publication)
    13. Tai WM, Tan SH, Tan DMY, Loke KSH, Ng DCE, Yan SX, Hwang JSG, Lim KH, Loh LM, Kek PC, Goh BKP, Lee SY, Chung AYF, Ong SY (2019). Clinicopathologic Characteristics and Survival of Patients with Gastroenteropancreatic Neuroendocrine Neoplasm in a Multi-Ethnic Asian Institution. Neuroendocrinology, 108(4), 265-277. (Read full publication)
    14. Suriyanto, Ng EY, Say XJ, Ng CE, Yan XS, Kumar S (2016). Quantitative means for differentiating renal obstruction by analysing renography by compartmental modelling of renal fluid flow rate. Nuclear medicine communications, 37(9), 904-10. (Read full publication)
    15. Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng C (2016). National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver cancer, 5(2), 97-106. (Read full publication)
    16. Tong AK, Zhang ZX, Zaheer S, Yan X (2016). Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan. Clinical imaging, 40(3), 486-91. (Read full publication)
    17. PKH Chow, SP Choo, Dce Ng, SX Yan, et al (2016). Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B. Liver cancer, 5(2), 91-6. (Read full publication)
    18. Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, Ko YH, Choi S, Jung SH, Khong PL, Tang T, Yan X, Lim ST, Kwong YL, Kim WS, Asia Lymphoma Study Grou (2015). Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. The Lancet. Haematology, 2(2), e66-74. (Read full publication)
    19. Yan X, Kang J, Zhou Y, Ehsan R, Halkar R, Applegate KE, Schuster D (2013). Imaging quality of F-18-FDG PET/CT in the inpatient versus outpatient setting. Annals of nuclear medicine, 27(6), 508-14. (Read full publication)
    20. Yin X, Yan X, Yang Q, Cao H, Liang (2010). Antitumor mechanism of recombinant murine interleukin-12 vaccine. Cancer biotherapy & radiopharmaceuticals, 25(3), 263-8. (Read full publication)
    21. Yin XL, Yan X, Wen M, Peng ZP, Li S (2010). Synergistic antitumor effects of 131I-LC-1 IgM and IL-12 vaccine on Lewis lung carcinoma. International immunopharmacology, 10(3), 284-9. (Read full publication)
    22. Macias-Perez I, Borza C, Chen X, Yan X, Ibanez R, Mernaugh G, Matrisian LM, Zent R, Pozzi (2008). Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer. Cancer research, 68(15), 6127-35. (Read full publication)
    23. Zent R, Yan X, Su Y, Hudson BG, Borza DB, Moeckel GW, Qi Z, Sado Y, Breyer MD, Voziyan P, Pozzi (2006). Glomerular injury is exacerbated in diabetic integrin alpha1-null mice. Kidney international, 70(3), 460-70. (Read full publication)
    24. Cai J, Kirlin WG, Chen Y, Yan X, Jones DP, Sartorelli A (2006). Overexpression of heat shock factor 1 inhibits butyrate-induced differentiation in colon cancer cells. Cell stress & chaperones, 11(3), 199-207. (Read full publication)
    25. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, Morrow JD, Capdevila J (2004). Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. The Journal of biological chemistry, 279(28), 29797-804. (Read full publication)
    26. Bakin AV, Stourman NV, Sekhar KR, Rinehart C, Yan X, Meredith MJ, Arteaga CL, Freeman M (2005). Smad3-ATF3 signaling mediates TGF-beta suppression of genes encoding Phase II detoxifying proteins. Free radical biology & medicine, 38(3), 375-87. (Read full publication)
    27. Sekhar KR, Yan XX, Freeman M (2002). Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2. Oncogene, 21(44), 6829-34. (Read full publication)
    28. Li SL, Yan XX, Liu X (1997). Uptake of 99mTc(5+)-complexes in ischemic myocardial slices and their dissociable ability. Zhongguo yao li xue bao = Acta pharmacologica Sinica, 18(5), 465-7. (Read full publication)

    Review

    1. Low HC, Tay YS, Ong SYK, Tham WY, Yan S (2023). Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide. Clinical nuclear medicine, 48(12), 1086-1088. (Read full publication)
    2. Phua VJX, Yang CT, Xia B, Yan SX, Liu J, Aw SE, He T, Ng DC (2022). Nanomaterial Probes for Nuclear Imaging. Nanomaterials (Basel, Switzerland), 12(4), (Read full publication)
    3. Appaduray SP, Khoo J, Somasundaram N, Chan J, Yan S (2020). Early Detection of Secondary Central Nervous System Lymphoma on PET/CT. Clinical nuclear medicine, 45(5), e254-e257. (Read full publication)
    4. Yang CT, Hattiholi A, Selvan ST, Yan SX, Fang WW, Chandrasekharan P, Koteswaraiah P, Herold CJ, Gulyás B, Aw SE, He T, Ng DCE, Padmanabhan (2020). Gadolinium-based bimodal probes to enhance T1-Weighted magnetic resonance/optical imaging. Acta biomaterialia, 110, 15-36. (Read full publication)
    5. Huang HL, Tong AKT, Thang SP, Yan SX, Lam WWC, Loke KSH, Tang CYL, Cheng LTJ, Ooi GSK, Low HC, Magsombol BM, Tham WY, Goh CXY, Tan CJ, Khor YM, Zaheer S, Bharadwaj P, Xie W, Ng DC (2019). Current Status and Growth of Nuclear Theranostics in Singapore. Nuclear medicine and molecular imaging, 53(2), 96-101. (Read full publication)

    Case Report

    1. Khor YM, Yan (2015). Benign fibrous histiocytoma of the thoracic spine as the cause of pyrexia of unknown origin identified by positron emission tomography/computed tomography. The spine journal, 15(7), 1691-2. (Read full publication)
    2. Tong AK, Mann KP, Schuster DM, Yan (2014). A rare presentation of myocardial plasmacytoma assessed by FDG PET/CT. Clinical nuclear medicine, 39(7), 643-5. (Read full publication)

    Editorial

    1. Lu Y, Yan SX, Lan X, Zhu X, Macapinlac H (2020). Nuclear medicine in responding to global pandemic COVID-19-American College of Nuclear Medicine member experience. European journal of nuclear medicine and molecular imaging, 47(7), 1620-1622. (Read full publication)